PE20110103A1 - Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas - Google Patents

Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas

Info

Publication number
PE20110103A1
PE20110103A1 PE2010001176A PE2010001176A PE20110103A1 PE 20110103 A1 PE20110103 A1 PE 20110103A1 PE 2010001176 A PE2010001176 A PE 2010001176A PE 2010001176 A PE2010001176 A PE 2010001176A PE 20110103 A1 PE20110103 A1 PE 20110103A1
Authority
PE
Peru
Prior art keywords
activity
modulator
compound
chemokine receptors
piperidinyl
Prior art date
Application number
PE2010001176A
Other languages
English (en)
Spanish (es)
Inventor
Joseph B Santella
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20110103A1 publication Critical patent/PE20110103A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2010001176A 2008-06-25 2009-06-25 Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas PE20110103A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7539408P 2008-06-25 2008-06-25
US12/490,477 US8299098B2 (en) 2008-06-25 2009-06-24 Piperidinyl derivative as a modulator of chemokine receptor activity

Publications (1)

Publication Number Publication Date
PE20110103A1 true PE20110103A1 (es) 2011-02-14

Family

ID=41060069

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001176A PE20110103A1 (es) 2008-06-25 2009-06-25 Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas

Country Status (24)

Country Link
US (2) US8299098B2 (enExample)
EP (1) EP2323983B1 (enExample)
JP (1) JP5357965B2 (enExample)
KR (1) KR20110023865A (enExample)
CN (1) CN102076663B (enExample)
AU (1) AU2009262219B2 (enExample)
BR (1) BRPI0914539A2 (enExample)
CA (1) CA2729016A1 (enExample)
CL (1) CL2010001566A1 (enExample)
CO (1) CO6321247A2 (enExample)
CY (1) CY1114994T1 (enExample)
DK (1) DK2323983T3 (enExample)
EA (1) EA021224B1 (enExample)
ES (1) ES2447740T3 (enExample)
HR (1) HRP20140071T1 (enExample)
IL (1) IL209832A (enExample)
MX (1) MX2010013664A (enExample)
NZ (1) NZ589909A (enExample)
PE (1) PE20110103A1 (enExample)
PL (1) PL2323983T3 (enExample)
PT (1) PT2323983E (enExample)
SI (1) SI2323983T1 (enExample)
TW (1) TWI433838B (enExample)
WO (1) WO2009158452A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
WO2011044197A1 (en) * 2009-10-07 2011-04-14 Bristol-Myers Squibb Company Spirocyclic compounds as modulators of chemokine receptor activity
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
AR087277A1 (es) 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos
US20150225790A1 (en) 2012-04-25 2015-08-13 Bristol-Myers Squibb Company Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist
US9257178B1 (en) * 2014-11-26 2016-02-09 Taiwan Semiconductor Manufacturing Company Limited Devices and methods for writing to a memory cell of a memory
EP3507830A4 (en) * 2016-08-31 2020-04-01 Micron Technology, Inc. MEMORY CELLS AND MEMORY MATRICES

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163855A (ja) 1984-02-06 1985-08-26 Mitsubishi Chem Ind Ltd アルギニン誘導体および薬剤として許容され得るその酸付加塩
GB9104656D0 (en) 1991-03-05 1991-04-17 Zambeletti Spa L Pharmaceuticals
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
WO1997003060A1 (en) 1995-07-13 1997-01-30 Senju Pharmaceutical Co., Ltd. Piperazine derivatives and use of the same
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP4024309B2 (ja) 1996-10-22 2007-12-19 第一三共株式会社 新規な感染症治療薬
US5847148A (en) 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
JPH1171350A (ja) * 1997-06-17 1999-03-16 Takeda Chem Ind Ltd ヒドロキシピペリジン化合物およびその剤
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
KR20010087125A (ko) * 1998-04-16 2001-09-15 데이비드 비. 맥윌리암스 인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물
DE69925160T2 (de) 1998-12-17 2006-02-16 Wyeth Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
US6489354B1 (en) 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
JP2004516237A (ja) * 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのピペリジンアミド類
DE10049699A1 (de) * 2000-10-07 2002-05-08 Bosch Gmbh Robert Anker für eine elektrische Maschine sowie Verfahren zu dessen Herstellung
EP1370558B1 (en) 2001-01-23 2005-08-24 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6887924B2 (en) 2001-05-11 2005-05-03 Multisorb Technologies, Inc. Pressed adsorbent and method of fabrication thereof
DE10124041A1 (de) 2001-05-16 2002-11-21 Graffinity Pharm Design Gmbh Protease Inhibitoren
US7115628B2 (en) 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20030229067A1 (en) * 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
BR0215202A (pt) * 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
GB0224917D0 (en) 2002-10-25 2002-12-04 Novartis Ag Organic compounds
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
RU2006100190A (ru) 2003-06-13 2006-08-10 Шеринг Акциенгезельшафт (De) Производные хинолиламида в качестве антагонистов ccr-5
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
DE10358539A1 (de) * 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
WO2005084672A1 (de) * 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1763347A4 (en) 2004-06-28 2009-05-20 Incyte Corp 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
GEP20094843B (en) 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
US7723360B2 (en) 2004-08-06 2010-05-25 Boehringer Ingelheim International Gmbh Alkyl-and piperidine-substituted benzimidazole derivatives
CA2598460C (en) * 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
JP5292400B2 (ja) 2007-07-24 2013-09-18 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体
EP2173713B1 (en) 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
AR087277A1 (es) 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos

Also Published As

Publication number Publication date
US8633226B2 (en) 2014-01-21
EP2323983A1 (en) 2011-05-25
US8299098B2 (en) 2012-10-30
TWI433838B (zh) 2014-04-11
KR20110023865A (ko) 2011-03-08
PT2323983E (pt) 2014-03-26
EA201100088A1 (ru) 2011-06-30
PL2323983T3 (pl) 2014-05-30
CN102076663B (zh) 2013-07-17
US20130023564A1 (en) 2013-01-24
ES2447740T3 (es) 2014-03-12
BRPI0914539A2 (pt) 2015-12-15
US20090326010A1 (en) 2009-12-31
CL2010001566A1 (es) 2011-05-13
HRP20140071T1 (hr) 2014-02-14
EA021224B1 (ru) 2015-05-29
CO6321247A2 (es) 2011-09-20
CN102076663A (zh) 2011-05-25
NZ589909A (en) 2012-04-27
JP5357965B2 (ja) 2013-12-04
TW201004927A (en) 2010-02-01
SI2323983T1 (sl) 2014-04-30
IL209832A (en) 2014-09-30
AU2009262219B2 (en) 2014-03-13
CA2729016A1 (en) 2009-12-30
DK2323983T3 (da) 2014-03-31
HK1154003A1 (en) 2012-04-13
JP2011526293A (ja) 2011-10-06
EP2323983B1 (en) 2014-01-01
MX2010013664A (es) 2011-01-14
CY1114994T1 (el) 2016-12-14
AU2009262219A1 (en) 2009-12-30
IL209832A0 (en) 2011-02-28
WO2009158452A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
NZ592255A (en) Folate receptor binding conjugates of antifolates
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
CL2008001636A1 (es) Compuestos derivados de bencimidazol, antagonistas de los receptores de angiotensina ii de tipo 1; proceso de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica de los compuestos; y su uso para tratar la hipertension, insuficiencia cardiaca.
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
EA201170703A1 (ru) Производные адамантилбензамида
EA200870197A1 (ru) Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms)
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed